TRANSLATE

The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Outcomes following allo-HSCT in patients with BP-MPN

By Dylan Barrett

Share:

Feb 9, 2023

Learning objective: After reading this article, learners will be able to cite a new clinical development in blast phase MPN.


Blast phase (BP) transformation of myeloproliferative neoplasms (BP-MPN) is characterized by ≥20% blasts in the peripheral blood and bone marrow and generally confers an adverse prognosis with a median overall survival (OS) of 3–5 months.1 While intensive chemotherapy is the current standard of care, many patients with BP-MPN are unfit for such treatment.1

The MPN Hub previously reported on outcomes in patients with BP-MPN treated with venetoclax combinations. Despite initial reposes following chemotherapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is necessary to translate these responses into long-term survival benefits and remains the only potentially curative option for patients with BP-MPN.1 Donor availability is a limiting factor of allo-HSCT and further analysis is required to determine the optimal patient selection strategy.1

Ortí et al.1 recently published an article in the American Journal of Hematology on a retrospective, multicenter analysis of patients with BP-MPN who underwent allo-HSCT, and we are pleased to summarize the key findings below.

Study design and patient characteristics

A retrospective analysis was performed with patient data from 169 institutions using the European Society for Blood and Marrow Transplantation (EMBT) registry. The analysis included 663 patients aged ≥18 years with BP-MPN treated with allo-HSCT between 2005 and 2019.

The primary endpoint was OS, with progression-free survival (PFS), non-relapse mortality (NRM), cumulative incidence of relapse (CIR), and cumulative incidences of graft-versus-host-disease (GvHD) and GvHD relapse-free survival after allo-HSCT as secondary endpoints. The median age was 60 years with a median follow-up of 5.2 years.

Results

Engraftment response

Graft failure was reported in 5.5% of patients. Response data 100 days post allo-HSCT were available for 528 patients, with:

  • 76% of patients in complete remission (CR);
  • 9% of patients relapsed or had progressive disease; and
  • 16% who were never in CR.

The 3- and 5-year OS was 36% and 32%, respectively, with a median OS of 13.9 months. The 5-year OS probability was significantly impacted by Karnofsky prognostic score, active disease, and the year of allo-HSCT, while the type of donor trended towards significance (Table 1).

Table 1. 5-year OS probability*

Allo-HSCT, allogeneic hematopoietic stem cell transplantation; CR, complete remission; MMRD, mismatch related donor; MMUD, mismatch unrelated donor; MSD, matched sibling donor; MUD, matched unrelated donor.
*Adapted from Ortí, et al.1

Characteristic, %

5-year OS probability

p value

Karnofsky prognostic score

 

 

              ≥90 (n = 367)

36

<0.001

              <90 (n = 240)

26

 

Year of allo-HSCT

 

 

              <2010 (n = 132)

23

0.02

              2010–2014 (n = 292)

34

 

              2015–2019 (n = 239)

34

 

Donor type

 

 

              MSD (n = 188)

32

0.06

              MMRD (n = 58)

25

 

              MUD (n = 231)

37

 

              MMUD (n = 121)

24

 

Disease stage at allo-HSCT

 

 

              CR (n = 291)

37

<0.001

              Active disease (n = 360)

27

 

Cause of death

In total, 436 patients died, with cause of death data available for 421 patients. The leading causes of death included:

  • Disease relapse or progression (45%)
  • Infection (30%)
  • GvHD (14%)
  • Organ damage or organ failure (5%)
  • Other transplant-related causes (3%)
  • Other causes (2%)
  • Secondary malignancies (1%)

Relapse and progression were the most common causes of death among patients who received allo-HSCT from mismatch sibling donor (MSD), mismatch unrelated donor (MMUD), matched unrelated donor (MUD), and matched unrelated donor, while infection was more common in patients who received allo-HSCT from mismatch related donor (MMRD).

Non-relapse mortality

Overall, the estimated 3- and 5-year NRM was 24% and 24%, respectively. Subgroup analysis revealed estimated 5-year NRM rates were higher in patients:

  • Who received allo-HSCT from a MMRD (41%) versus a MSD (17%), MUD (22%), and MMUD (28%; p < 0.001)
  • Who received post-transplant cyclophosphamide (38%) versus post-transplant calcineurin inhibitors (22%) or any other form of GvHD prophylaxis (31%; p = 0.01)
  • With a Karnofsky prognostic score <90 (33%) versus ≥90 (19%; p < 0.001)
  • Undergoing allo-HSCT with active disease (29%) versus patients in CR (19%; p < 0.001)
  • Who received a graft from other graft sources (34%) versus peripheral blood (23%; p = 0.04)

Cumulative incidences of relapse

The 3- and 5-year CIR was 48% and 51% respectively. The 5-year CIR was higher in patients receiving post-transplant calcineurin inhibitors (53%) compared with patients receiving post-transplant cyclophosphamide (38%; p = 0.04).

Progression-free survival

The estimated 3- and 5-year PFS was 28% and 25%, respectively, with a median PFS of 7.8 months. The 5-year PFS was higher in patients:

  • Who received allo-HSCT between 2015–2019 (29%) and 2010–2014 (27%) versus 2005–2010 (16%; p = 0.01)
  • With a Karnofsky prognostic score ≥90 (27%) versus <90 (22%; p = 0.01)
  • Who received allo-HSCT in CR (29%) versus those who received allo-HSCT with active disease (22%; p < 0.001)

Multivariate analysis

Multivariate analysis using multivariable Cox proportional hazard models determined the following:

  • Karnofsky performance score <90 (p < 0.0001), year of allo-HSCT (p = 0.004), and active disease at transplant (p = 0.0007) influenced OS
  • Karnofsky performance score <90 (p = 0.003), year of allo-HSCT (p = 0.006), and active disease at transplant (p = 0.0005) influenced PFS
  • Active disease at transplant (p = 0.02) influenced relapse rates
  • Karnofsky performance score <90 (p = 0.0002), overall donor type (p = 0.01), MMRD (p = 0.005), MMUD (p = 0.05), and active disease at transplant (p = 0.004) influenced NRM
  • Age at allo-HSCT (per 10-year increase), sex, interval diagnosis-acute myeloid leukemia, and stem cell source were not significant factors in terms of OS, PFS, relapse, and NRM

GvHD

The 100-day cumulative incidences of GvHD Grade II–IV and III–IV acute GvHD were 29% and 13%, respectively. The 100-day cumulative incidences of acute GvHD were higher in patients who received total body irradiation-based conditioning (38%) than in patients who received non-total body irradiation-based conditioning (27%; p = 0.02).

Post-transplant treatment

Post allo-HSCT data were available for 285 patients, of which 62% received disease-related treatment and 20% received a donor lymphocyte infusion.

Conclusion

This large, retrospective analysis showed that survival outcomes are poor in patients with BP-MPN who underwent allo-HSCT. However, outcomes have improved in recent years, with significantly improved outcomes from 2010 onward. Patients with a Karnofsky prognostic score ≥90 and who underwent allo-HSCT in remission also experienced improved survival outcomes. Prospective studies are warranted and may improve patient selection for allo-HSCT.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content